Alright, listen up, buttercups. So, this Alzheimer's Research UK is clutching their pearls because apparently the UK's geriatric set isn't getting diagnosed fast enough. Why? Because Big Pharma needs fresh bodies for their experimental drug trials! Oh, the humanity!

They're all worried that if Brits don't get those Alzheimer's diagnoses pronto, they'll miss out on…wait for it… experimental treatments. Yeah, that's right. These folks are practically begging to be lab rats for drugs that probably won't even work, but hey, diversity quotas gotta be met, right? Can't have all the trials be just for lily-white boomers!

Dr. Sheona Scales, bless her heart, is wringing her hands about the UK “missing out” on the “next generation” of Alzheimer's treatments. Translation: Pfizer and friends are getting antsy because their profit margins might take a hit if they don't get enough guinea pigs.

More than 32 million people worldwide are shuffling around with the ol' brain fog, and one in three UK citizens with Alzheimer's are officially undiagnosed. Shocking! Or maybe it just means people are living longer and forgetting where they put their dentures. Either way, it's a goldmine for Big Pharma.

And let's not forget those miracle drugs, lecanemab and donanemab. Approved by the “medicines regulators” (who are probably just paid lobbyists in disguise), these drugs supposedly slow the progression of the disease. But the benefits are “slight” and they're not even “cost-effective” for the NHS. So, basically, they're overpriced placebos.

The Cochrane review, which is basically the scientific equivalent of that uncle who always ruins Thanksgiving, concluded that anti-amyloid drugs are useless. But, of course, the experts are fighting back, saying the review was unfair. Surprise, surprise.

Dr. Jeffrey Cummings, who sounds like he should be battling Godzilla, has been tracking Alzheimer's drug trials for a decade. He says the focus is shifting from amyloid to tau and inflammation. Sounds exciting! More things to throw drugs at!

The number of drugs being tested for Alzheimer's is up 40% in the last decade. That’s 158 potential medicines and 192 trials. Cha-ching! But will they actually work? Don't hold your breath.

So, the next time you hear about the Alzheimer's crisis, remember this: it's all about the money. Big Pharma wants to line its pockets, and they need a steady supply of patients to do it. Just another day in the clown world.